|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400082351 |
|
最近更新日期: Date of Last Refreshed on: |
2024-03-27 10:41:29 |
|
注册时间: Date of Registration: |
2024-03-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于老年综合评估的老年肌少症住院患者营养---运动干预方案的构建及疗效分析 |
|
Public title: |
Construction and therapeutic analysis of nutrition exercise intervention plan for hospitalized elderly patients with sarcopenia based on comprehensive geriatric assessment |
|
注册题目简写: |
老年肌少症患者营养运动干预构建 |
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于老年综合评估的老年肌少症住院患者营养---运动干预方案的构建及疗效分析 |
|
Scientific title: |
Construction and therapeutic analysis of nutrition exercise intervention plan for hospitalized elderly patients with sarcopenia based on comprehensive geriatric assessment |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨秀芬 |
研究负责人: |
杨秀芬 |
|
Applicant: |
YANG xiufen |
Study leader: |
YANG xiufen |
|
申请注册联系人电话: Applicant telephone: |
+86 153 6401 5967 |
研究负责人电话:
Study leader's |
+86 153 6401 5967 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1757083108@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
1757083108@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
深圳市罗湖区东门北路1017号大院 |
研究负责人通讯地址: |
深圳市罗湖区东门北路1017号大院 |
|
Applicant address: |
Courtyard, No. 1017 Dongmen North Road, Luohu District, Shenzhen |
Study leader's address: |
Courtyard, No. 1017 Dongmen North Road, Luohu District, Shenzhen |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
深圳市人民医院 |
||
|
Applicant's institution: |
Shenzhen People's Hospital |
||
|
研究负责人所在单位: |
深圳市人民医院 |
||
|
Affiliation of the Leader: |
Shenzhen People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
LL-KY-2023135-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
深圳市人民医院科研伦理委员会 |
||
|
Name of the ethic committee: |
Research Ethics Committee of Shenzhen People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-08-11 00:00:00 | ||
|
伦理委员会联系人: |
骆瑜 |
||
|
Contact Name of the ethic committee: |
Luoyu |
||
|
伦理委员会联系地址: |
深圳市罗湖区东门北路1017号大院 |
||
|
Contact Address of the ethic committee: |
Courtyard, No. 1017 Dongmen North Road, Luohu District, Shenzhen |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 135 1050 8336 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
深圳市人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shenzhen People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
深圳市罗湖区东门北路1017号大院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Courtyard, No. 1017 Dongmen North Road, Luohu District, Shenzhen |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
院内科研基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Internal Medicine Research Fund of the Hospital |
||||||||||||||||||||||
|
研究疾病: |
肌少症 |
||||||||||||||||||||||
|
Target disease: |
sarcopenia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
(1)构建一套适用于老年肌少症住院患者的营养运动干预方案; (2)探讨干预方案的可行性和安全性,分析其对老年肌少症住院患者肌肉质量、肌肉力量、活动能力以及生活质量的影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) Develop a nutritional exercise intervention plan suitable for hospitalized elderly patients with sarcopenia; (2) Explore the feasibility and safety of intervention plans, and analyze their impact on muscle mass, muscle strength, activity ability, and quality of life of hospitalized elderly patients with sarcopenia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)纳入标准 ①符合 2019 版亚洲肌少症诊断策略: a 肌肉力量:最大握力男性<28kg,女性<18kg; b 躯体功能:5 次起坐试验≥12s; c 骨骼肌含量:以上下肢骨骼肌质量指数(SMI)为准,计算方法为四肢骨骼肌质量(kg)与身高的平方(m)的比值,生物电阻抗法(BIA)诊断范围为男性<7.0kg/㎡,女性<5.7kg/㎡。 骨骼肌含量降低+肌肉力量降低/躯体功能下降者,视为肌少症。 ②年龄 ≥60 岁; ③BI 指数 ≥40 分; ④无语言沟通障碍、可配合完成量表评估者; ⑤既往无规律运动习惯; ⑥患者及家属知情同意,自愿加入。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Inclusion criteria ① Compliant with the 2019 diagnostic strategy for Asian sarcopenia: Muscle strength: maximum grip strength for males<28kg, females<18kg; Physical function: 5 sit up tests for ≥ 12 seconds; Skeletal muscle content: The lower limb skeletal muscle mass index (SMI) is used as the standard, and the calculation method is the ratio of limb skeletal muscle mass (kg) to the square of height (m). The diagnostic range of bioelectrical impedance (BIA) is less than 7.0kg/m2 for males and less than 5.7kg/m2 for females. A decrease in skeletal muscle content, muscle strength, or physical function is considered sarcopenia. ② Age ≥ 60 years old; ③ BI index ≥ 40 points; ④ Individuals who have no language communication barriers and can cooperate in completing scale assessments; ⑤ Previous irregular exercise habits; ⑥ The patient and their family members voluntarily join with informed consent. |
||||||||||||||||||||||
|
排除标准: |
(2)排除标准 ①体内装有心脏起搏器、接受过人工关节置换或截肢手术患者; ②伴有不可逆转的严重并发症或恶性肿瘤、重要脏器功能衰竭等重症患者; ③内生肌酐清除率(Ccr)少于 30ml/min,平常对蛋白质摄入量需严格控制的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(2) Exclusion criteria ① Patients with a pacemaker installed in their body, who have undergone artificial joint replacement or amputation surgery; ② Severe patients with irreversible complications or malignant tumors, important organ failure, etc; ③ Patients who have an endogenous creatinine clearance rate (Ccr) of less than 30ml/min and require strict control of protein intake. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-06-01 00:00:00至 To 2025-06-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-03-31 00:00:00 至 To 2025-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
No |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
数据收集完成后以论文形式公开 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After data collection is completed, it will be published in the form of a paper |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
Data collection is mainly conducted through paper questionnaires, and data management is mainly carried out using EXCELL software. |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection is mainly conducted through paper questionnaires, and data management is mainly carried out using EXCELL software. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |